LH
Labcorp Holdings Inc.Evidence as of 2026-09-03Overview · Labcorp Holdings Inc.
Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics and Labcorp Drug Development. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests,…
Management team
- Mr. Akinbolade Oyegunwa M.B.A., Ph.D. · Executive VP and Chief Information & Technology OfficerFind on LinkedIn
- Mr. Glenn A. Eisenberg · Executive VP & Special Advisor to the CEOFind on LinkedIn
- Ms. Anita Z. Graham · Executive VP & Chief Human Resources OfficerFind on LinkedIn
- Dr. Brian J. Caveney J.D., M.D., M.P.H. · EVP, President of Early Development Research Laboratories and Chief Medical & Scientific OfficerFind on LinkedIn
Start your 7-day free trial to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it — not a rating or a recommendation.
+0.4 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled — the rest of the page is the evidence behind it.
The desk’s surviving claims show a constructive evidence balance: Constructive (+0.4 of a possible +2; was +0.4 before debate) · confidence high. Labcorp’s reported top-line and margins expanded in the most recent reported period, with revenues of $ 3,731,100,000 and gross profit of $ 1,112,000,000 in fiscal Q2 2026 (fiscal quarter ended 2026-08-04), up from $ 3,527,300,000 in fiscal Q2 2025 (fiscal quarter ended 2025-07-31) and $ 3,537,600,000 in fiscal Q1 2026 (fiscal quarter ended 2026-05-01). Operating income rose to $ 451,600,000 and operating margin widened to about 12.1% in fiscal Q2 2026; net income was $ 298,700,000 with diluted EPS of $ 3.64, and weighted-average diluted shares declined to 82,000,000.
The balance sheet snapshot in the surviving claims shows cash and cash equivalents falling from $ 981,100,000 as of 2026-03-31 to $ 141,800,000 as of 2026-06-30 while long-term debt noncurrent increased modestly to $ 5,857,600,000. Valuation metrics recorded in the evidence include a trailing twelve-month PE of 25.61 on EPS (TTM) $ 12.95 and an EV/EBITDA of 14.58 on an enterprise value of $ 32,960,826,000, alongside trailing EBITDA of $ 2,260,200,000 and trailing operating income of $ 1,623,500,000.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else — no outside knowledge, no browsing — so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC — revenue, margins, income, debt and share count, quarter by quarter — and reports which way the trend is running.
Revenues were $3,731,100,000 in fiscal Q2 2026 (2026-04-01 to 2026-06-30, 3mo) versus $3,537,600,000 in fiscal Q1 2026 (2026-01-01 to 2026-03-31, 3mo) and $3,527,300,000 in fiscal Q2 2025 (2025-04-01 to 2025-06-30, 3mo).
XBRL companyfacts · 0000920148-26-000175Gross profit was $1,112,000,000 in fiscal Q2 2026 and $1,013,800,000 in fiscal Q1 2026, implying gross margin rose from about 28.7% in fiscal Q1 2026 to about 29.8% in fiscal Q2 2026 (1,112,000,000 / 3,731,100,000).
XBRL companyfacts · 0000920148-26-000175Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Nothing in this slice of the evidence rose to a claim — a quiet read, which itself is information.
Which filings the desk reads
The desk reads the annual 10-K in full — its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet — its risk analysis fills in once that lands.
Reads the signal panel above — momentum, volatility, drawdown, relative strength and beta — and ranks each against the whole research universe rather than judging it in isolation.
No computed signal history for this symbol yet — signals need roughly 70 trading days of price history.
Reads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
Labcorp Holdings Inc. was a holding in the iShares Core S&P 500 ETF (IVV) with a reported weight of 0.04% of the fund as of 2026-09-02T13:45:47.228469+00:00.
ETF constituents · market dataweakened in debateThe single reported membership data point shows a small position size within that major index ETF (0.04% weight), indicating factual exposure but not implying any change in ownership or insider activity.
ETF constituents · market dataweakened in debateReads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
Multiple outlets carried Labcorp's announcement of enhancements to its Labcorp Global Trial Connect digital platform on 31 August 2026.
News · prnewswire.com · 2026-08-31A syndicated version of the Labcorp Global Trial Connect launch appeared on Yahoo Finance on 31 August 2026, indicating the same company-specific product announcement was distributed across outlets.
News · finance.yahoo.com · 2026-08-31Reads parsed Forms 3/4/5 — who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
No insider transactions on file in the trailing 180 days.
Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
Trailing twelve-month free cash flow (FCF) was negative $157,600,000 as of the data in this file.
Valuation inputs · SEC XBRL + stored EOD closeTrailing twelve-month EBITDA was $2,260,200,000 and trailing operating income was $1,623,500,000.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score — the argument is shown, not hidden, so you can judge the reasoning yourself.
Several company-reported fundamentals point toward improving core performance: sequential and year-over-year revenue growth, rising gross and operating margins, and higher net income and diluted EPS in fiscal Q2 2026 versus Q1 2026. The firm also reduced diluted share count and disclosed share repurchases, which mechanically supported EPS and demonstrates capital return activity. On a profitability basis, trailing EBITDA and operating income are strong relative to the capital structure, and the trailing P/E of ~25.6 sits alongside these earnings figures. Recent product and platform announcements (an FDA-cleared pTau-217 test and enhancements to a clinical-trial platform) are company-specific evidence of revenue-adjacent innovation and go-to-market activity. These points jointly support a favorable read on operating momentum and earnings quality, while liquidity and cash-flow items warrant attention when assessing financial flexibility.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.37
22 surviving claims rest on 11 distinct sources; the heaviest analyst carries 32% of them, and 89% of what the desk raised survived the debate.
The read rests on a moderate breadth of sources but a relatively small analyst concentration and high survival rate, so the desk’s conclusions are internally consistent but somewhat brittle to a few key inputs. Because a third of surviving claims trace back to the heaviest analyst and 89% of debated points survived, new primary-source updates (a filing or price shock) would materially change how much weight to place on this set of claims.
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment — when the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here — no outside knowledge, no browsing — and each card shows who read it and what it contributed to the score.
11 filings· 1 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data — not retyped or estimated.
Read by Mercer+0.9 to the score
1 holdings record
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.0 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only — it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal — the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
Get this for the tickers you actually hold
Plus the one thing no sample can show: how each name correlates with your portfolio, and what hides inside your funds.
The full terminal on LH Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.